Recently, "clinical trial anticancer drugs entering the market" have attracted industry attention, and the drug involved is Kangfang Biopharma's cardunilimab. On June 4, Kangfang Biopharma provided reporters with a "Statement on News Reports on a Cervical Cancer Patient in Chongqing Using the Company's Drugs", stating that after investigation and verification: the company has never charged patient Li Moumei any fees for the clinical research drugs used by Li Moumei, and the company's sales staff have not charged any fees to the patient Li Moumei. In other words, there is no situation where the patient "spends money to buy clinical research drugs". The statement mentioned that the company's Chongqing sales staff forged research project documents and hospital ethics approval materials, and defrauded several drugs from the company in the name of post-marketing clinical research initiated by researchers, and gave them to patient Li Moumei for free. According to the sales staff: the drug was provided to Li Moumei for free many times, mainly because they considered that Li Moumei's ability to pay was very limited, and the efficacy of cardunilimab injection has been good since she used it. Kangfang Bio emphasized that the drugs obtained free of charge by patient Li Moumei were produced strictly in accordance with national GMP standards and were subject to the same strict drug quality management requirements as the company's commercially sold products.